Bracco Imaging S.p.a.

Bracco International Bv

Dibra S.p.a.

Luciano Lattuada

Fulvio Uggeri

Roberta Napolitano

Rolf E Swenson

Silvio Aime

Kondareddiar Ramalingam

Edmund R Marinelli

Enrico Cappelletti

Valeria Boi

Pierfrancesco Morosini

Karen E Linder

Michael F Tweedle

Palaniappa Nanjappan

Pier Lucio Anelli

Natarajan Raju

Massimo Visigalli

Giovanni Battista Giovenzana

Roberta Fretta

Federica Buonsanti

Adrian D Nunn

Christoph De Haen

Giovanna Lux

Camilla Cavallotti

Alberto Fringuello Mingo

Elisa Battistini

Michele Serleti

Maria Argese

Attilio Citterio

Carlo Scolastico

Alessandro Maiocchi

Marino Brocchetta

Federico Maisano

Enzo Terreno

Daniela Delli Castelli

Sonia Gazzetto

Zsolt Baranyai

Gabriella Leonardi

Leonardo Manzoni

Herv&eacute; Tournier

Laura Galimberti

Fulvia Vella

Livio Cavalieri

Giuseppe Marazzi

Aurelia Ferrigato

Milena Gabellini

Matteo Galli

Nicole Guidolin

Gabriele Meli

Evelin Vignale

Daniela Arosio

Daniela Imperio

Bo Song

Mario Virtuani

Federico Crivellin

Ornella Gazzotti

Andrea Beltrami

Giuseppe Manfredi

Luisella Calabi

Silvia Ceragioli

Lorena Pizzuto

Roberta Mazzon

Alessandro Barge

Daniela Palano

Laura Orio

Giovanni Rivolta

Loredana Sini

Massimo Sisti

Giovanni Palmisano

Armando Mortillaro

Giancarlo Cravotto

Anthony Clouet

Eliana Gianolio

Alberto Vertova

Carlo Morelli

Giuseppe Ferrauto

Letizia Sorti

Alessandro Minguzzi

Vito Lorusso

Mary Ellen Maddalena

Davide Belnome

Lorena Beltrami

Linda Chaabane

Raphael Campanella

Francesca Baricco

Fulvio Ferretti

Ramalingam Kondareddiar

Hervé Tournier

Pier Francesco Morosini

Ivan Menegotto

Livio Cavaliere

Frederica Buonsanti

The present invention refers to pharmaceutical compositions comprising a macrocyclic gadolinium complex and a water-soluble polyarylene additive useful in diagnostic imaging as diagnostic agents, in particular as contrast agents, specifically in Magnetic Resonance Imaging (MRI).

Pharmaceutical compositions comprising Gd-complexes and polyarylene additives

The invention is related to a process for preparing a iodinating X-rays contrast agent. More specifically, it relates to a process for the preparation of N,N'-bis-(2,3-dihydroxypropyl)-5-hydroxy-2,4,6-triiodo-1,3-benzenedicarboxaniide (I) by electrochemical iodination of N,N′-(2,3-dihydroxypropyl)-5-hydroxy-1,3-benzenedicarboxamide (II) with molecular iodine (I2) which is in situ electrochemically generated from a source of iodide ions (I−). The iodide ions (I−) are obtained by the dissolution of hydrogen iodide (HI) or an alkali metal iodide in the reaction medium or produced during the reaction of N,N′-(2,3-dihydroxypropyl)-5-hydroxy-1,3-benzenedicarboxamide with I2. The invention also relates to the use of the intermediate compound of formula (I), obtained through the above electrochemical iodination of compound (II), in the preparation of N,N′-bis[2,3-dihydroxypropyl]-5(hydroxyacetyl)methylamino]-2,4,6-triiodo-1,3-benzenedicarboxamide (iomeprol).

Electrochemical iodination of N,N'-(2,3-dihydroxypropyl)-5-hydroxy-1,3-benzenedicarboxamide

The present invention relates to the RRR/SSS pair of enantiomers of the of Gd(PCTA-tris-glutaric acid), the single enantiomers of the pair, the pharmaceutically acceptable salts thereof, their amide derivatives, and compositions comprising at least 50% of these compounds.

Gadolinium bearing PCTA-based contrast agents

The invention relates to a process for preparing Gadoteridol of formula (I). In particular, the process comprises the use of propylene oxide in the alkylation step of the compound of formula (II), wherein propylene oxide is directly reacted with the compound of formula (II) without being isolated, and wherein propylene oxide is obtained on demand by decomposition of propylene carbonate in the presence of an alkaline or alkaline earth metal halide as catalyst.

Manufacturing process for preparing gadoteridol

The present invention relates to new class of dimeric macrocycles capable of chelating paramagnetic metal ions, their chelated complexes with metal ions and the use thereof as contrast agents, particularly suitable for Magnetic Resonance Imaging (MRI) analysis.

Dimeric contrast agents

The present invention relates to new class of functionalized macrocycles capable of chelating paramagnetic metal ions, their chelated complexes with metal ions and the use thereof as contrast agents, particularly suitable for Magnetic Resonance Imaging (MRI) analysis.

Contrast agents

The present invention relates to new class of functionalized polyazamacrocycles including at least one phosphonic or phosphinic group linked to a nitrogen atom of the macrocyclic cage, and capable of chelating paramagnetic metal ions, their chelated complexes with metal ions and the use thereof as contrast agents, particularly suitable for Magnetic Resonance Imaging (MRI) analysis.

The application relates to a process for the synthesis of a Near Infra-Red (NIR) fluorescent probe which is a cRGD-Cy5.5 conjugate of formula (I) known as DA364 comprising an aza-bicycloalkane based cyclic peptide labelled with a Cy5.5 dye moiety and used in the guided surgery of tumors and pathologic regions. 

Synthesis of NIR fluorescent probe

The present invention generally relates to a process using a mechanochemical approach exploiting the mechanical milling of reactants for the manufacturing of acetyl Iopamidol and, more generally, of key intermediates of radiographic contrast agents, and of the contrast agents themselves.

Mechanochemical synthesis of radiographic agents intermediates

The present invention discloses a solid-phase process for the preparation of a Near Infra-Red (NIR) fluorescent probe characterized by an aza-bicycloalkane based cyclic peptide labelled with a Cy5.5 dye moiety and used in the guided surgery of tumors and pathologic regions.

Solid phase synthesis of NIR fluorescent probe

The present invention relates to new class of dimeric macrocycles capable of chelating paramagnetic metal ions, their chelated complexes with the paramagnetic metal ions and the use thereof as contrast agents, particularly suitable for Magnetic Resonance Imaging (MRI) analysis.

The present invention relates to a process for the preparation of the mono sodium salt of the derivative 3,5-diiodo-O-[3-iodo-4-(sulphooxy)phenyl]-L-tyrosine (T3S) by starting from the corresponding phenolic compound, in the presence of chlorosulfonic acid and dimethylacetamide as a solvent. The so obtained T3S compound may conveniently be isolated in a pure form as a solid in good yields. The present invention further relates to the process for T3S preparation, wherein the starting reagent is T2 and further comprising the formulation of such compound in tablets. Furthermore, the invention discloses non-radioactive immunoassays based on T3S derivatives.

Process for the preparation of a sulfated derivative of 3,5-diiodo-o-[3-iodophenyl]-l-tyrosine

Growing community of inventors

Bussero, Italy

Luciano Lattuada